Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II
- 1 January 1990
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 26 (5), 586-589
- https://doi.org/10.1016/0277-5379(90)90083-6
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugsEuropean Journal of Cancer and Clinical Oncology, 1989
- Effect of minor groove binding drugs on mammalian topoisomerase I activityBiochemical Pharmacology, 1989
- DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cellsBiochemistry, 1989
- Selectivity of N-[2-(Dimethylamino)ethyl]acridine-4-car☐amide towards Lewis lung carcinoma and human tumour cell lines in vitroEuropean Journal of Cancer and Clinical Oncology, 1989
- Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase IIEuropean Journal of Cancer and Clinical Oncology, 1988
- Binding of Hoechst 33258 to the minor groove of B-DNAJournal of Molecular Biology, 1987
- Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamideJournal of Medicinal Chemistry, 1987
- Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase IIScience, 1984
- Nonintercalative DNA-binding antitumour compoundsMolecular and Cellular Biochemistry, 1982
- Inhibition of condensation of human Y chromosome by the fluorochrome Hoechst 33258 in a mouse-human cell hybridHuman Genetics, 1979